Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (LIBerate-OLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04798430

Recruitment Status : Enrolling by invitation

First Posted : March 15, 2021

Last Update Posted : March 29, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Medpace, Inc.

Information provided by (Responsible Party):

LIB Therapeutics LLC

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Enrolling by invitation
Estimated Primary Completion Date :	October 30, 2024
Estimated Study Completion Date :	December 31, 2024

To Top